BioIntelliSense is a technology company.
BioIntelliSense has raised $25.0M across 1 funding round.
BioIntelliSense has raised $25.0M in total across 1 funding round.
BioIntelliSense has raised $25.0M in total across 1 funding round.
BioIntelliSense's investors include Asylum Ventures, Divergent Capital, Goat Capital, Goodwater Capital, Oak HC/FT, Pareto Holdings, Y Combinator, Kyle Vogt.
# BioIntelliSense: Continuous Health Monitoring for the Modern Healthcare System
BioIntelliSense is a medical device and data analytics company that develops FDA-cleared wearable biosensors and cloud-based clinical intelligence platforms for continuous patient monitoring[1][2]. The company serves hospitals, health systems, and remote patient monitoring programs by automating vital sign capture and enabling early detection of patient deterioration[2][4].
The core problem BioIntelliSense solves is the inefficiency and incompleteness of traditional healthcare monitoring. Conventional vital sign checks occur only at discrete intervals—typically every few hours in hospitals or episodically in remote settings—creating gaps where patient decline goes undetected[6]. BioIntelliSense replaces this fragmented approach with continuous, multi-parameter monitoring that captures thousands of physiologic measurements daily on a single wearable device[5]. The company's Data-as-a-Service (DaaS) platform then applies advanced analytics and AI to surface actionable clinical insights, enabling clinicians to intervene earlier and more effectively[4][5].
BioIntelliSense's competitive advantages center on three dimensions:
BioIntelliSense operates at the intersection of three powerful healthcare trends: remote patient monitoring (RPM) expansion, hospital workforce shortages, and early intervention economics.
The healthcare system faces mounting pressure to deliver more care with fewer resources. Nursing shortages and rising labor costs make continuous automated monitoring increasingly attractive compared to manual vital sign checks[4]. Simultaneously, payers and providers recognize that early detection of deterioration—whether in hospital or at home—prevents costly emergency interventions and readmissions. BioIntelliSense's continuous data model directly addresses this: as one clinician noted, traditional RPM is "like a photograph," while continuous monitoring is "like a high resolution 4K video"[6].
The company's timing is particularly favorable. FDA clearance of wearable biosensors has accelerated, reimbursement codes for RPM have expanded, and health systems are actively seeking technology solutions to manage patient volumes amid staffing constraints[4]. BioIntelliSense's partnerships with major health systems like Ardent Health Services (30 hospitals) and integrations with leading virtual care platforms like VeeMed signal growing ecosystem adoption[4][6].
BioIntelliSense is well-positioned to capture significant market share in the continuous monitoring space as hospitals and health systems prioritize patient safety and operational efficiency. The company's FDA-cleared devices, reimbursement model, and clinical validation create defensible competitive advantages. Key growth vectors include hospital system expansion, post-acute care deployment, and integration with broader virtual care ecosystems[4][5].
The broader trend working in their favor is the shift from episodic to continuous care—a fundamental reimagining of how healthcare systems monitor and respond to patient needs. As labor shortages persist and healthcare economics tighten, continuous automated monitoring will likely become standard rather than exceptional. BioIntelliSense's early mover advantage in medical-grade wearables and clinical analytics positions them to shape this transition.
BioIntelliSense has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in July 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2019 | $25.0M Series A | Asylum Ventures, Divergent Capital, Goat Capital, Goodwater Capital, Oak HC/FT, Pareto Holdings, Y Combinator, Kyle Vogt |